Who is sponsoring NCT00712920?

NCT00712920 is sponsored by Meda Pharmaceuticals.

What drugs are being tested in NCT00712920?

Interventions in NCT00712920: 0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, Placebo.

What condition does NCT00712920 study?

NCT00712920 studies Perennial Allergic Rhinitis.

Is NCT00712920 still recruiting?

NCT00712920 is currently completed. Last updated 6 June 2011.

Are results published for NCT00712920?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2011-06-06 · How we verify

NCT00712920

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 and MP03-33 in Patients With Perennial Allergic Rhinitis

Completed Phase 3 Results posted Last updated 6 June 2011

What this trial tests

Phase 3 trial testing 0.15% azelastine hydrochloride in Perennial Allergic Rhinitis in 581 participants. Completed.

Timeline

1 January 2007

Primary endpoint
1 May 2008

Quick facts

Lead sponsor	Meda Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	581
Start date	1 January 2007
Primary completion	1 May 2008
Sites	43 locations across United States

Drugs / interventions tested

0.15% azelastine hydrochloride — full drug profile →
0.1% azelastine hydrochloride — full drug profile →
Placebo

Conditions studied

Perennial Allergic Rhinitis — all drugs for Perennial Allergic Rhinitis →

Sponsor

Meda Pharmaceuticals — full company profile →

Who can join

12 and older, any sex, with Perennial Allergic Rhinitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (AM and PM Combined) at 28 Days.
Time frame: baseline and 28 days
Reflective total nasal symptom score consisting of Runny nose, itchy nose, nasal Congestion, and Sneezing was assessed twice daily. Each symptom is rated on a scale from 0-3: 0=none, 1=mild, 2=moderate, and 3=severe. Total possible score is 24 per day Least square means (LS Mean) was controlled for study day as the within-patient effect, treatment group and site as the between-patient effects, tr

Sponsor's own description

The purpose of this study is to determine if two allergy medications are more effective than placebo.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A double-blind, placebo-controlled trial of the efficacy and safety of two doses of azelastine hydrochloride in perennial allergic rhinitis.
Bousquet J, Klimek L, Kuhl HC, Nguyen DT, et al · · 2023 · cited 4× · PMID 37920410 · DOI 10.3389/falgy.2023.1244012

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00712920 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Meda Pharmaceuticals
Last refreshed: 6 June 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00712920.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing